Biotech News

Liquidia Corporation Reports Third Quarter 2026 Financial Results

Liquidia Corporation (LQDA)Liquidia CorporationEarnings

YUTREPIA® (treprostinil) inhalation powder net product sales of $222.7 million in the third quarter of 2026, up 31% from the second quarter of 2026 October 2026 total patient shipments reached their highest monthly level since launch Resolved all litigation with United Therapeutics through a global

Related news

Liquidia Corporation

Pulmonary Hypertension Company Liquidia develops and commercializes therapies for pulmonary hypertension. Its product strategy applies particle-engineering technology to improve delivery of established medicines. YUTREPIA YUTREPIA is a dry-powder formulation of treprostinil delivered through a compact, low-effort inhaler. It is approved...

Recent company news

Stock data

Close
56.63 USD
Market cap
4.9B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States